Read More 5 minute read Pharma Industry News AstraZeneca’s Fasenra misses primary endpoint in COPD trial but keeps investor confidence alive AstraZeneca’s Fasenra failed to hit its COPD trial endpoint, but stock rose 0.44% as investors bet on pipeline strength and respiratory growth. byPallavi MadhirajuSeptember 17, 2025